8-K: Kalaris Therapeutics Secures $50M Private Placement

Kalaris Therapeutics, a clinical-stage biopharmaceutical company, announced an oversubscribed private placement raising approximately $50.0 million to advance its lead retinal disease candidate, TH103.

Summary

• Kalaris Therapeutics, Inc. entered into a securities purchase agreement on December 17, 2025, for a private placement with institutional accredited investors.
• The company agreed to issue and sell an aggregate of 4,200,000 shares of common stock at $10.00 per share.
• Additionally, 800,000 pre-funded warrants to purchase common stock were sold at $9.9999 per pre-funded warrant, with an exercise price of $0.0001 per share.
• The private placement is expected to generate aggregate gross proceeds of approximately $50.0 million, before deducting placement agent fees and offering expenses.
• The closing of the private placement is anticipated on or about December 19, 2025, subject to customary closing conditions.
• The company expects the net proceeds, combined with existing cash, to fund operations into the third quarter of 2027.
• Proceeds are intended to advance the clinical development of TH103 for neovascular AMD, and for working capital and other general corporate purposes.
• Morgan Stanley & Co. LLC and Leerink Partners LLC acted as lead placement agents, with William Blair & Company, L.L.C. also acting as a placement agent.
• Kalaris Therapeutics has agreed to file a registration statement for the resale of the shares and shares underlying the pre-funded warrants by April 6, 2026.

Sentiment

Score: 7

Explanation: The successful, oversubscribed private placement significantly strengthens the company's financial position, extending its cash runway and enabling continued clinical development. While inherent risks of a clinical-stage biotech remain, the funding provides a strong positive signal for its strategic execution.

Positives

• The private placement was oversubscribed, indicating strong investor confidence and demand.
• Successfully raised approximately $50.0 million in gross proceeds, significantly bolstering the company's financial resources.
• The capital raise extends the company's cash runway into the third quarter of 2027, providing operational stability for an extended period.
• Funds are earmarked for advancing the clinical development of TH103 for neovascular AMD, a key strategic objective.
• Participation from both new and existing institutional investors, including prominent names like ADAR1 Capital Management, Coastlands Capital, Invus, RTW Investments, Samsara BioCapital, and Woodline Partners LP.

Negatives

• The issuance of 4,200,000 new shares of common stock and 800,000 pre-funded warrants will result in dilution for existing shareholders.
• Gross proceeds of $50.0 million will be reduced by placement agent fees and other offering expenses, impacting the net amount available to the company.

Risks

• Risks associated with the clinical development and regulatory approval of TH103, including potential delays in completing clinical trials.
• Uncertainties regarding the therapeutic benefits, clinical potential, and clinical development of TH103.
• Challenges in the timing of and ability to enroll patients in clinical trials.
• Preclinical study results and initial data from early clinical trials may not be predictive of final results of later clinical trials or future trials.
• Risk of inability to obtain sufficient additional capital to continue advancing product candidates.
• Uncertainties in obtaining successful clinical results for product candidates and potential unexpected costs.
• Risks related to the failure to realize any value from product candidates due to inherent difficulties in bringing them to market.
• Challenges in obtaining, maintaining, and protecting intellectual property rights related to product candidates.
• Potential impact from changes in regulatory requirements and government incentives.
• Risks related to Kalaris' competitive position and developments from competitors or competing therapies.
• Risk of involvement in current and future litigation.
• General economic, political, industry, and market conditions could adversely affect the company.
• Securities issued by a current or former shell company (Kalaris' predecessor, AlloVir, Inc., was a shell company prior to March 18, 2025 merger) are subject to Rule 144(i) restrictions, meaning they cannot be sold in reliance on Rule 144 until one year after the company is no longer a shell company and has filed current Form 10 information, and is current on SEC reporting requirements.

Future Outlook

Kalaris Therapeutics expects its existing cash, cash equivalents, and short-term investments, together with the anticipated net proceeds from the private placement, will be sufficient to fund the company's operating expenses and capital expenditure requirements into the third quarter of 2027. The company intends to use these funds to advance the clinical development of TH103 for neovascular AMD and for working capital and other general corporate purposes.

Management Comments

• Kalaris expects its existing cash, cash equivalents, and short term investments, together with the net proceeds from the private placement, will enable it to fund operations into the third quarter of 2027.
• Kalaris intends to use the net proceeds from the private placement, together with its existing cash, cash equivalents, and short term investments to advance the clinical development of TH103 for neovascular AMD and for working capital and other general corporate purposes.

Industry Context

Kalaris Therapeutics operates as a clinical-stage biopharmaceutical company dedicated to developing treatments for prevalent retinal diseases, specifically focusing on neovascular AMD with its lead candidate, TH103. The company's foundation by Dr. Napoleone Ferrara, a pioneer in anti-VEGF therapy, positions it within a critical and competitive segment of ophthalmology. This capital raise provides essential funding to continue R&D efforts in a field characterized by high development costs and significant unmet medical needs, where successful innovation can lead to substantial market opportunities.

Corporate Governance

Stakeholder Impact

• Shareholders: Experience dilution from the issuance of new common stock and potential future exercise of pre-funded warrants. However, the capital raise significantly strengthens the company's financial position, which could support long-term value creation and reduce the risk of near-term financial distress.
• Participating Investors: Gain an equity stake in Kalaris Therapeutics at a premium to recent trading prices, with a contractual right to have their shares registered for resale, providing a path to liquidity.
• Employees: Benefit from enhanced job security and the continued funding of R&D programs, which supports the company's strategic objectives and growth.
• Patients/Customers: The capital infusion directly supports the advancement of TH103 for neovascular AMD, potentially leading to new or improved treatment options for prevalent retinal diseases.
• Creditors: The extended cash runway and improved financial liquidity reduce the company's short-term credit risk, making it a more stable borrower.

Next Steps

• The private placement is expected to close on or about December 19, 2025.
• Kalaris Therapeutics will file a registration statement covering the resale of the shares and pre-funded warrant shares as promptly as reasonably practicable following April 1, 2026, and in any event no later than five days following such date.
• The company plans to advance the clinical development of TH103 for neovascular AMD using the net proceeds from the private placement.

Key Dates

Keywords

Kalaris Therapeutics, KLRS, Private Placement, Biopharmaceutical, Retinal Diseases, TH103, Neovascular AMD, Clinical Stage, Capital Raise, SEC Filing, Warrants, Common Stock, Institutional Investors, Cash Runway